BACKGROUND: Neoadjuvant chemotherapy in pure urothelial bladder cancer provides a significant survival benefit. However, to the authors' knowledge, it is unknown whether this benefit persists in histological variants. The objective of the current study was to assess the effect of neoadjuvant chemotherapy on the probability of non-organ-confined disease and overall survival after radical cystectomy (RC) in patients with histological variants. METHODS: Querying the National Cancer Data Base, the authors identified 2018 patients with histological variants who were undergoing RC for bladder cancer between 2003 and 2012. Variants were categorized as micropapillary or sarcomatoid differentiation, squamous cell carcinoma, adenocarcinoma, neuroendocrine tumors, and other histology. Logistic regression models estimated the odds of non-organ-confined disease at the time of RC for each histological variant, stratified by the receipt of neoadjuvant chemotherapy. Cox regression models were used to examine the effect of neoadjuvant chemotherapy on overall mortality in each variant subgroup. . CONCLUSIONS: Patients with neuroendocrine tumors benefit from neoadjuvant chemotherapy, as evidenced by better overall survival and lower rates of non-organ-confined disease at the time of RC. For tumors with micropapillary differentiation, sarcomatoid differentiation, or adenocarcinoma, neoadjuvant chemotherapy decreased the frequency of non-organ-confined disease at the time of RC. However, this favorable effect did not translate into a statistically significant overall survival benefit for these patients, potentially due to the aggressive tumor biology. Cancer 2017;123:4346-55.
INTRODUCTION
Bladder cancer is the most common neoplasm of the urinary tract, with an estimated 76,960 newly diagnosed cases in 2016. 1 Urothelial histology, which represents >90% of all bladder neoplasms, is mostly diagnosed in its pure form. 2 Nonetheless, the incidence of nonpure urothelial histological variants or differentiations previously has been reported to range from 7% to 81%. [3] [4] [5] Multiple retrospective studies and smaller cases series have demonstrated that these histological variants are associated with adverse pathological features and poor outcomes. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, differences in prognosis are not as apparent when adjusted for disease stage. In addition, it has been shown that nonpure urothelial histological variants demonstrate a different response to systemic therapies in a palliative setting compared with those with pure urothelial histology. 16 Nevertheless, this cannot be translated into generalized recommendations regarding perioperative chemotherapy for patients with localized muscle-invasive bladder cancer. Although there is clear evidence that neoadjuvant chemotherapy (eg, cisplatin and etoposide) provides a survival benefit in patients with neuroendocrine tumors, 17 to our knowledge its role remains uncertain for other nonpure urothelial histological variants, such as those with micropapillary or sarcomatoid differentiation. In a recent secondary analysis of the Southwest Oncology Groupdirected intergroup randomized trial S8710, there was evidence of a survival benefit from neoadjuvant chemotherapy in patients with urothelial tumors with squamous and glandular components. 18 However, whether this is true for patients with nonurothelial pure squamous cell carcinoma and adenocarcinoma or other histological variants remains unknown.
To the best of our knowledge, evidence concerning perioperative chemotherapy in the treatment of patients with the aforementioned histological variants is scarce and quite divergent. For example, a small case series found recently that the presence of nonpure urothelial histological variants was associated with lower rates of complete response to neoadjuvant chemotherapy. 19 Conversely, another study reported higher odds of pathological downstaging (pT1N0) in patients with these histological variants 20 compared with patients with pure urothelial histology. Nonetheless, a poor response to cisplatin-based regimens generally has been observed in the literature and it currently is difficult to decipher whether this is a reflection of the tumor biology or advanced disease stage. 21 Based on these considerations, we queried the National Cancer Data Base (NCDB) to conduct comparative analyses of histopathological outcomes and overall survival between patients receiving neoadjuvant chemotherapy before radical cystectomy (RC) versus RC alone to treat the most common nonpure urothelial histological variants.
MATERIALS AND METHODS

Data Source
The NCDB is a joint cancer registry by the Commission on Cancer of the American College of Surgeons and the American Cancer Society and was established in 1989. Greater than 1500 Commission on Cancer-accredited institutions from the United States and Puerto Rico contribute data and approximately 70% of all newly diagnosed cancer cases are captured. Over the years, the NCDB has become an important comprehensive cancer surveillance source in the United States as standardized data regarding patients, hospitals, and course of treatment are collected, coded, and reported.
Study Population and Treatment Groups
The NCDB participant user file for 1998 through 2012 contains 603,298 patients diagnosed with urinary bladder cancer (International Classification of Diseases for Oncology, 3rd Edition [ICD-O-3] topography codes C67.0-C67.9). We used the American Joint Committee on Cancer staging system 22 to select those patients with clinically localized muscle-invasive disease (cT2N0M0) or limited pelvic lymph node burden (cT2N1M0) because these represent subsets of individuals who are potentially curable. Staging criteria for inclusion were determined by 2 medical oncologists (T.K.C. and J.B.) based on those from several recent neoadjuvant chemotherapy trials. [23] [24] [25] Using the ICD-O-3 classification, only those patients with the most common nonpure urothelial histological variants, including those with micropapillary or sarcomatoid differentiation and neuroendocrine tumors as well as squamous cell carcinoma and adenocarcinoma, were considered. 26 In addition, we created a comprehensive "other histology" category (see Supporting Information Table  1) , which included variants with numbers too low to have power for analysis. A further inclusion criterion was the receipt of RC as the most definitive surgical procedure. In addition, we relied on the chemotherapy variable to distinguish between patients who received and those who did not receive systemic cytotoxic treatment. Neoadjuvant chemotherapy was defined as any chemotherapy administered as the first course of treatment within 180 days before RC. Variables indicating the interval between chemotherapy and the most definitive surgery of the primary tumor site were introduced into the NCDB in 2003 and therefore patients diagnosed before 2003 were excluded, which yielded a final study population of 2018 patients (Fig. 1 ).
Covariables and Endpoints
We abstracted patient demographics and socioeconomic, hospital, and clinical characteristics as indicated and grouped in Table 1 .
Primary endpoints of the current study were favorable and unfavorable pathological criteria, defined as complete treatment response (pT0 rates), and non-organconfined disease (pT3/4 and/or pN1), respectively, at the time of RC. The secondary analytic endpoint was overall survival from the time of initial diagnosis to the date of death from any cause or censorship at the time of last follow-up. For both endpoints, we compared patients receiving neoadjuvant chemotherapy before RC versus RC alone in the aforementioned histological subgroups.
Statistical Analyses
We reported means and standard deviations for continuous variables, and categorical variables were reported using frequencies and percentages. Differences between the treatment groups within each histological subgroup were assessed using the Student t test and chi-square test, as appropriate.
We calculated the percentages of patients with pT0 and non-organ-confined disease at the time of RC for each of these histological variants stratified according to the receipt of neoadjuvant chemotherapy before RC compared with RC alone. Using univariable and multivariable logistic regression models, we estimated the unadjusted and adjusted odds ratios (ORs) for non-organ-confined disease in patients receiving neoadjuvant chemotherapy for each nonpure urothelial histological variant separately. Multivariable logistic regression analyses were adjusted for age, sex, race, Charlson-Deyo comorbidity index, clinical stage, radiotherapy, facility location, facility type, and county type. Before performing survival analyses, patients with missing follow-up data or missing information regarding vital status were excluded (260 patients). Kaplan-Meier curves for each histological variant subgroup were calculated to compare overall survival between patients who received neoadjuvant chemotherapy before RC versus those who were treated with RC only. The log-rank test was used to test for equality of overall survival in both treatment groups. In addition, we performed univariable and multivariable Cox regression analyses to compute adjusted hazard ratios for the impact of neoadjuvant chemotherapy on overall mortality in each of the nonpure urothelial histological variant subgroups. Multivariable Cox regression analyses were adjusted for age, sex, Charlson-Deyo comorbidity index, clinical stage, radiotherapy, and adjuvant chemotherapy within 180 days after RC. To assess the impact of immortal time bias, 27 we conducted a sensitivity analysis by repeating our survival analyses using a conditional landmark at 6 months. To control for optimistic prediction in small samples, multivariable logistic and Cox regression analyses were bootstrap-corrected (200 samples). 28 All statistical analyses in the current study were performed using Stata statistical software (Version 14.0; StataCorp LP, College Station, Texas). All the reported P values were 2-sided and values <.05 were considered to be statistically significant.
RESULTS
Overall, 2018 patients fit our inclusion criteria; 369 (18.3%) received neoadjuvant chemotherapy before RC and 1649 (81.7%) underwent RC only. The median follow-up for patients alive at the time of last follow-up was 50.9 months (interquartile range, 32.6-75.2 months).
Baseline Characteristics
Patients receiving neoadjuvant chemotherapy were younger, more likely to be male, and privately insured. In addition, they underwent perioperative radiotherapy more often compared with the patients undergoing RC alone. There were no other significant differences noted between the 2 treatment groups ( (Table 3) .
Overall Survival Analyses
The median overall survival in each variant stratified by treatment is shown in Table 4 . In univariable KaplanMeier analyses, a difference in overall survival for neoadjuvant chemotherapy versus RC was observed only for neuroendocrine tumors (P 5.001, log-rank test) (Fig. 2E) whereas there was no statistically significant difference in overall survival observed between the 2 treatment groups for any other nonpure urothelial histological variant (all P.1) (Figs. 2A-2D and 2F). The conditional landmark survival analyses excluding those patients who died within 6 months of diagnosis (261 patients) demonstrated similar results (see Supporting Information Fig. 1A-1F ). Adjusted multivariable Cox regression analyses demonstrated a significant overall survival benefit for neoadjuvant chemotherapy in patients with neuroendocrine tumors (hazard ratio, 0.49; 95% CI, 0.33-0.74 [P5.001]) compared with patients undergoing RC only. Conversely, there were no significant differences in survival noted between the treatment groups in any other histological subsets (all P>.07) ( Table 4) . Similar results were observed using the conditional landmark analysis excluding patients who died within 6 months of diagnosis (see Supporting Information Table 3 ). 
DISCUSSION
In the setting of pure urothelial bladder cancer, there is a well-established 5% survival benefit in eligible patients treated with neoadjuvant chemotherapy followed by RC compared with patients treated with RC alone. 29 This, however, cannot be translated into an equal benefit for Original Article
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Cancer patients diagnosed with nonpure urothelial histological variants. Most often, those individuals have been excluded from large randomized controlled trials and, as a result, omitted from the systematic reviews and meta-analyses. Presumably, this could be related to the infrequency of variant histology in the general population as well as distinct biological behavior. Against this backdrop, evaluating and generating evidence regarding their specific clinical response to systemic therapy has been dependent on case series with very small sample sizes. 19, 20 To the best of our knowledge, this comprehensive study is the first to assess the role of neoadjuvant chemotherapy for the most common nonpure urothelial histological variants at a broader level. Although there was a statistically significant overall survival benefit for neoadjuvant chemotherapy found in patients with neuroendocrine tumors, no other histological subtypes conferred a survival advantage. However, patients with micropapillary differentiation, sarcomatoid differentiation, adenocarcinoma, and neuroendocrine tumors were less likely to harbor non-organconfined disease at the time of RC, when they received such treatment before undergoing surgery.
With regard to neuroendocrine tumors, the findings of the current study align with previous evidence supporting a survival benefit with the use of systemic therapy, especially in a neoadjuvant setting. 30, 31 Although neuroendocrine tumors account for <1% of all bladder cancers, they are extremely aggressive, with 94% of patients presenting with muscle-invasive disease and up to 67% of patients developing metastases. 32 As such, National Comprehensive Cancer Network guidelines recommend treating them as a systemic disease from the time of diagnosis. 33 However, this evidence is derived mostly from small case series. For example, a single-center retrospective evaluation of 46 patients demonstrated that the 5-year cancer-specific survival rate was 36% in patients with neuroendocrine tumors undergoing RC alone versus 78% in those who received neoadjuvant chemotherapy. 31 In the current study population, we found that overall survival was improved by 51% in patients with neuroendocrine tumors who received neoadjuvant chemotherapy versus RC alone. In addition, there was a decrease of 84% in the probability of non-organ-confined disease at the time of RC after receipt of neoadjuvant chemotherapy. Intriguingly, despite these results and those of former reports, we observed that only 46.5% of patients with neuroendocrine tumors received neoadjuvant chemotherapy. Presumably, this might reflect the present lack of consensus regarding adequate treatment for this malignancy.
In the current literature, there is conflicting evidence supporting a potential survival benefit with neoadjuvant chemotherapy for patients with micropapillary and sarcomatoid differentiations. Despite promising anecdotal complete responses to neoadjuvant chemotherapy (pT0) in patients with those variants, 34, 35 some reports have shown that there was no translation into a survival advantage, potentially due to the aggressiveness of the differentiations. 21, 36 The results of the current study demonstrated similar results, with a 70% and 60%, respectively, decrease in non-organ-confined disease, but no overall survival benefit noted. In a previous case series including 44 patients with micropapillary muscle-invasive disease, approximately 45% of those patients who received neoadjuvant chemotherapy demonstrated a complete pT0 response at the time of RC. 34 It is interesting to note that those patients with pT0 had a far better overall and recurrence-free survival at 24 months (92% vs 25% and 79% vs 21%, respectively). 34 In the current study population, patients with squamous cell carcinoma or adenocarcinoma did not appear to benefit from neoadjuvant chemotherapy in terms of overall survival. It is interesting to note that patients with squamous cell carcinoma and adenocarcinoma have been shown to be more likely to die of local than systemic progression, 26 thus providing a strong rationale to achieve early pelvic tumor control with RC and adjuvant radiotherapy. 21 As such, the role of systemic therapy for those variants, particularly in the neoadjuvant setting, appears to be marginal. Intriguingly, we observed that patients receiving neoadjuvant chemotherapy for squamous cell carcinoma trended toward poorer survival in our landmark analyses (see Supporting Information Fig. 1C ). Although these results were not statistically significant, a potential adverse effect of chemotherapy toward delayed definite surgery in those patients needs to be considered.
Given that treatment approaches in histological variants of the bladder are not standardized, a risk-adjusted therapy appears to be reasonable and is implemented in some centers. 21 Future considerations will focus on the main question within the context of neoadjuvant chemotherapy: how to identify those patients who would benefit from systemic treatment before surgery. A promising approach could be the identification and estimation of certain genetic markers, which provide information about the propensity of response to neoadjuvant chemotherapy. For example, there is evidence that ERBB2 mutations predict greater response to neoadjuvant chemotherapy, 37 and micropapillary tumors are known to have a higher rate of ERBB2 mutations.
One limitation of the current study is that the assessment of histologic variants was based on coding and not central pathological slide review. This most likely results in an underdiagnosis of nonpure urothelial histological variants due to an underrecognition of histologic variants among pathologists. 3 There are varying reports concerning the frequency of variants, which emphasizes the interobserver variability in the diagnosis of histological variants of bladder carcinoma, especially in small specimens or in specimens with a small amount of divergent differentiation. This also may contribute to the discordance between findings from one study to another. As such, although we only included patients who were assignable to differentiations or pure variant histologies based on ICD-O-3 codes, we acknowledge that some of them still may harbor mixed histology. Other limitations are related to the observational study design. Specifically, the current study analyses are subject to selection bias in baseline characteristics, which we attempted to account for by using multivariable Cox models. In addition, the NCDB does not provide information regarding the specific regimen of neoadjuvant chemotherapy; as such, we were unable to control for the use of cisplatin-based systemic chemotherapy or the number of cycles delivered. Thus, suboptimal, non-cisplatin-based protocols may have confounded our outcomes of interest. However, given that evidence concerning the superiority of one cytotoxic agent over the other is insufficient for the majority of variant histologies, we decided to include patients who received any chemotherapy within 180 days before RC. In the current study, we focused on overall survival as a primary outcome given that the NCDB does not provide any information regarding cancer-specific death. This may have led to further bias related to other-cause mortality, which we attempted to control for by including comorbidities into the multivariable models. Finally, as in any secondary data analysis, potential coding errors and underreporting of the histological variants due to nonstandardized templates to define the specific variants could have introduced further biases in the reported results. 38 
Conclusions
To summarize, the results of the current study report a significant overall survival benefit in patients with neuroendocrine tumors of the bladder who received neoadjuvant chemotherapy. Furthermore, a significant decrease in non-organ-confined disease at the time of RC was observed in those patients. Although patients with tumors with micropapillary differentiation, adenocarcinoma, and sarcomatoid differentiation demonstrated a similar decrease in pT3 and/or pN1 disease when they received neoadjuvant chemotherapy, this benefit does not appear to translate in statistically significant superior overall survival, potentially due to the aggressive biology. These findings should be interpreted within the context of the hypothesis-generating, retrospective study design. To draw further treatment conclusions, well-designed prospective evaluations of the role of systemic therapy in bladder histological variants are necessary.
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